Argent BioPharma Limited
RGT.L · LSE
6/30/2024 | 12/31/2023 | 6/30/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.01 | 0.00 | 0.00 |
| FCF Yield | -18.97% | -47.93% | -212.91% | -418.59% |
| EV / EBITDA | -3.91 | -2.62 | -0.45 | -1.36 |
| Quality | ||||
| ROIC | 500.87% | -39.57% | 144.26% | -97.69% |
| Gross Margin | -129.12% | 12.06% | 16.20% | 46.32% |
| Cash Conversion Ratio | 0.65 | 1.12 | 0.53 | 0.62 |
| Growth | ||||
| Revenue 3-Year CAGR | 16.95% | 32.99% | 103.91% | 150.16% |
| Free Cash Flow Growth | 14.29% | -55.75% | 30.91% | 2.07% |
| Safety | ||||
| Net Debt / EBITDA | -0.07 | -0.42 | -0.09 | -1.15 |
| Interest Coverage | -699.74 | -12.09 | -56.74 | -107.11 |
| Efficiency | ||||
| Inventory Turnover | 0.40 | 0.43 | 0.23 | 0.84 |
| Cash Conversion Cycle | 257.93 | -132.67 | -106.76 | -38.46 |